Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Accounts Payables (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Accounts Payables for 16 consecutive years, with $6.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables rose 7.55% to $6.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.0 million, a 7.55% increase, with the full-year FY2025 number at $6.0 million, up 7.55% from a year prior.
  • Accounts Payables was $6.0 million for Q4 2025 at Anika Therapeutics, up from $4.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $10.0 million in Q1 2024 to a low of $4.7 million in Q3 2025.
  • A 5-year average of $7.5 million and a median of $7.9 million in 2021 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: soared 31.47% in 2021, then tumbled 52.26% in 2025.
  • Anika Therapeutics' Accounts Payables stood at $7.6 million in 2021, then grew by 18.88% to $9.1 million in 2022, then plummeted by 31.74% to $6.2 million in 2023, then decreased by 9.32% to $5.6 million in 2024, then grew by 7.55% to $6.0 million in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Accounts Payables are $6.0 million (Q4 2025), $4.7 million (Q3 2025), and $4.8 million (Q2 2025).